Compare CAPR & HLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAPR | HLF |
|---|---|---|
| Founded | 2005 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2011 | 2004 |
| Metric | CAPR | HLF |
|---|---|---|
| Price | $19.50 | $12.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $44.63 | $18.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.7M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | N/A | ★ $5,037,500,000.00 |
| Revenue This Year | N/A | $4.97 |
| Revenue Next Year | $3.31 | $3.80 |
| P/E Ratio | ★ N/A | $21.10 |
| Revenue Growth | N/A | ★ 0.89 |
| 52 Week Low | $4.30 | $7.56 |
| 52 Week High | $40.37 | $20.40 |
| Indicator | CAPR | HLF |
|---|---|---|
| Relative Strength Index (RSI) | 28.96 | 44.99 |
| Support Level | $5.25 | $11.39 |
| Resistance Level | $30.39 | $13.21 |
| Average True Range (ATR) | 1.33 | 0.55 |
| MACD | -0.26 | -0.06 |
| Stochastic Oscillator | 16.93 | 18.15 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Herbalife Ltd is a health and wellness company. It provides health and wellness products in 95 markets through a direct-selling business model. Its product categories include Weight Management, Targeted Nutrition, Energy, Sports and Fitness, Outer Nutrition, and Literature, Promotional, and Other. Weight Management generates the majority of revenue, with products such as meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Products are manufactured at facilities in Changsha and Suzhou, China; Lake Forest, California; and Winston-Salem, North Carolina, as well as by third-party providers. Revenues reflect sales to Members across North America, Latin America, EMEA, Asia Pacific, and China.